Preliminary evaluation of serial interferon-gamma releasing assay testing in NSCLC patients treated with immune checkpoint inhibitors

K. Fujita (Kyoto, Japan), Y. Yamamoto (Kyoto, Japan), O. Kanai (Kyoto, Japan), M. Okamura (Kyoto, Japan), K. Nakatani (Kyoto, Japan), T. Mio (Kyoto, Japan)

Source: Virtual Congress 2020 – Tuberculosis: part 2
Session: Tuberculosis: part 2
Session type: Oral Presentation
Number: 5298
Disease area: Respiratory infections, Thoracic oncology

Congress or journal article abstractWebcastSlide presentationE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
K. Fujita (Kyoto, Japan), Y. Yamamoto (Kyoto, Japan), O. Kanai (Kyoto, Japan), M. Okamura (Kyoto, Japan), K. Nakatani (Kyoto, Japan), T. Mio (Kyoto, Japan). Preliminary evaluation of serial interferon-gamma releasing assay testing in NSCLC patients treated with immune checkpoint inhibitors. 5298

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.

Related content which might interest you:
Evaluation of serial interferon-gamma release assay testing in lung cancer patients treated with immune checkpoint inhibitors
Source: Virtual Congress 2021 – Challenges and advances in the diagnosis and clinical management of tuberculosis
Year: 2021

Serial interferon-gamma release assays for screening and monitoring of tuberculosis infection during treatment with biologic agents
Source: Annual Congress 2013 –Tuberculosis and latent tuberculosis infection in subpopulations
Year: 2013

Predictive biomarker of immune checkpoint inhibitors efficacy
Source: New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine
Year: 2019

The role of fibrocyte-like cells in combination treatment of immune checkpoint inhibitor with antiangiogenic agents
Source: Virtual Congress 2020 – Novel directions in pleural disease: bench to bedside
Year: 2020

An evaluation of the use of a negative interferon gamma release assay for tuberculosis screening before TNF antagonist therapy
Source: Eur Respir J 2014; 44: 1369-1372
Year: 2014

Dynamic monitoring of EGFR mutations in circulating tumor DNA for early detection of drug resistance in NSCLC patients on EGFR-TKI therapy
Source: International Congress 2019 – Diagnostic procedures and biology of lung cancer
Year: 2019

Use of immune cell function assay in immune surveillance of lung transplant recipients: Correlations with clinical outcome and other immune assays
Source: Annual Congress 2012 - Optimising outcomes after lung transplantation
Year: 2012

The clinical benefits of immune checkpoint inhibitors for thymic carcinomas
Source: International Congress 2018 – Clinical management of pleural malignancies, including mesothelioma
Year: 2018

Comparison of whole-blood interferon-gamma release assay and tuberculin skin test results for the prediction of active tuberculosis disease in HIV-infected individuals
Source: Annual Congress 2009 - Tuberculosis and HIV co-infection
Year: 2009

Diagnostic performance of the interferon gamma release assay in elderly patients and clinical factors to support the diagnosis of active tuberculosis
Source: Annual Congress 2012 - Tuberculosis and immunologic assays
Year: 2012

Clinical evaluation of interferon-gamma release assay (IGRA) in patients with nontuberculous mycobacterial disease
Source: Annual Congress 2012 - Non-tuberculous and tuberculous mycobacterial infections: from epidemiology to clinical findings
Year: 2012

Serial interferon-gamma release assay in children with tuberculosis infection
Source: Annual Congress 2010 - Tuberculosis in children
Year: 2010

Sequential analysis of interferon-γ release assay results in active tuberculosis patients
Source: Annual Congress 2009 - From bench to bedside: diagnosis of tuberculosis
Year: 2009

Clinical evaluation of two interferon-gamma release assay tests for immunocompromised patients
Source: Annual Congress 2010 - Interferon-gamma releases assays (IGRAs) for the diagnosis of tuberculosis: what is the role?
Year: 2010

The predictive value of circulating tumor DNA dynamics in plasma of EGFR-mutation-positive NSCLC patients on first line tyrosine kinase inhibitors
Source: Virtual Congress 2021 – New clinical and biological developments in lung cancer
Year: 2021

The efficacy of immune checkpoint inhibitors in thoracic malignancies
Source: Eur Respir Rev, 30 (162) 200387; 10.1183/16000617.0387-2020
Year: 2021

CellCollector®: A novel method for the isolation of circulating tumor cells (CTC) in vivo and ex vivo in lung cancer patients during therapy
Source: International Congress 2016 – Lung cancer and immune cells: friends or foes?
Year: 2016

Impaired detection of Mycobacterium tuberculosis immunity in patients using high levels of immunosuppressive drugs
Source: Eur Respir J 2009; 34: 702
Year: 2009

Support of ex vivo IFN-gamma release assays in the diagnosis of tuberculosis infection in HIV/AIDS patients
Source: Annual Congress 2008 - Interferon-gamma release assay tests for diagnosing tuberculosis infection and disease
Year: 2008

Immune checkpoint inhibitors in lung cancer
Source: International Congress 2016 – GR3 Scientific Grand Round: precision medicine
Year: 2016